Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BIOGAIA AB is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are distributed across 2 distinct examiners, meaning each pending matter is being handled by a different individual. This distribution is also reflected in the 2 distinct art units involved in the company's prosecution. The busiest examiner for the portfolio is HINES, JANA A, who is responsible for 1 busiest examiner pending action. This examiner handles 1 of the company's 2 pending office actions.
The presence of 2 distinct art units indicates that the company's Biotechnology & Pharmaceuticals innovations are being evaluated across different technical classifications. This variety in examiners and art units provides BIOGAIA AB with a broader range of feedback from the patent office. The prosecution strategy must account for the specific requirements of 2 art units to successfully resolve the 2 pending office actions. Practitioners should coordinate their approach to ensure consistency across the 2 distinct examiners while respecting the unique technical standards of each art unit. This diversified examiner engagement reduces the impact of any 1 examiner's decision on the overall portfolio. The company's focus on Biotechnology & Pharmaceuticals is currently split between these 2 active prosecution paths.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOAZZAMI, NAGHMEH NINA | 2 | 71.8% | +49.1% |
| HINES, JANA A | 1 | 53.2% | +39.4% |
| VAN BUREN, LAUREN K | 1 | 40.0% | +58.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002184 | GOS PRE-CONDITIONING L. REUTERI AND GOS IN FINAL FORMULATION | MOAZZAMI, NAGHMEH NINA | 14d |
| 18002163 | PRE-CONDITIONING OF L.REUTERI | MOAZZAMI, NAGHMEH NINA | 15d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18060626 | HISTAMINE-PRODUCING BACTERIAL STRAINS AND THEIR USE IN CANCER | VAN BUREN, LAUREN K | 51d overdue |
| 18002184 | GOS PRE-CONDITIONING L. REUTERI AND GOS IN FINAL FORMULATION | MOAZZAMI, NAGHMEH NINA | 14d |
| 18002163 | PRE-CONDITIONING OF L.REUTERI | MOAZZAMI, NAGHMEH NINA | 15d |
| 18510979 | Therapeutic Microvesicles of Probiotic Bacteria | HINES, JANA A | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1645 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18510979 | Therapeutic Microvesicles of Probiotic Bacteria | HINES, JANA A | 1645 | §103 | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18002184 | GOS PRE-CONDITIONING L. REUTERI AND GOS IN FINAL FORMULATION | MOAZZAMI, NAGHMEH NINA | 1652 | §102§103 | Final Rejection | 14d | Pending | Dec 16, 2022 |
| 18002163 | PRE-CONDITIONING OF L.REUTERI | MOAZZAMI, NAGHMEH NINA | 1652 | §102§103 | Final Rejection | 15d | Pending | Dec 16, 2022 |
| 18060626 | HISTAMINE-PRODUCING BACTERIAL STRAINS AND THEIR USE IN CANCER | VAN BUREN, LAUREN K | 1638 | §103 | Final Rejection | 51d overdue | Pending | Dec 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOGAIA AB has 4 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Naghmeh Nina Moazzami has the most, with 2 of BIOGAIA AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
